与联合口服避孕药相关的血栓栓塞事件:基于FDA不良事件报告系统 (FAERS) 数据库的现实研究
Yanhong Liu1, Guixin Zhao2, Rong Feng1
1Department of Pharmacy, Yunnan Maternal and Child Health Hospital, Kunming, China.
Expert opinion on drug safety
|December 6, 2024
概括
联合口服避孕药 (COCs) 增加了血栓栓塞事件 (TEE) 的风险. 含德罗斯皮伦的COC显示了最高的关联,早期监测对于患者的安全至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 血栓栓塞的事件 血栓塞的事件
背景情况:
- 结合口服避孕药 (COCs) 对血栓栓塞事件 (TEE) 的临床数据有限.
- 了解COC相关的TEE风险对于患者管理至关重要.
研究的目的:
- 评估与COC相关的TEE的风险和发病时间.
- 为了确定具有较高TEE风险的特定COC.
主要方法:
- 利用FAERS数据库进行药监测研究.
- 使用不成比例分析来识别安全信号.
- 应用韦布尔分析来确定TEE发病时间.
主要成果:
- 冠状动脉栓塞与静脉血栓栓塞 (VTE) 和动脉血栓塞 (ATE) 有着显著的联系.
- 含有德罗斯皮伦的COC显示了TEE报告频率最高的情况.
- TEE的中位发病时间为264天,VTE比ATE更早发生.
结论:
- 联合口服避孕药与TEE的风险增加有关.
- 由于风险较高,应特别注意含有多斯匹伦的COCs.
- 建议在COC治疗期间进行早期风险监测.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Disorders of Hemostasis
707
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
707
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K


